Loading...
•
Sep 30, 2021
RAPT Q3 2021 Earnings Report
RAPT Therapeutics reported financial results for the third quarter of 2021.
Key Takeaways
RAPT Therapeutics reported a net loss of $18.7 million for the third quarter of 2021, compared to a net loss of $14.6 million for the third quarter of 2020. Research and development expenses were $15.7 million, and general and administrative expenses were $3.8 million.
Advanced development of RPT193 in atopic dermatitis and FLX475 in cancer.
Presented additional incremental data for RPT193 at dermatology meetings.
Well positioned to advance RPT193 into Phase 2 clinical trials in atopic dermatitis and asthma in 2022.
Focused development of FLX475 in key indications, including EBV+ lymphoma, nasopharyngeal cancer and head and neck cancer.